Omrix Biopharmaceuticals, Inc. Sets IPO At 3.4 Million Shares, $15-$17/Share

March 27, 2006 |

1 min read

WASHINGTON, March 24 (Reuters) - Omrix Biopharmaceuticals Inc., which develops biosurgical and passive immunotherapy products, on Friday said it is planning to sell about 3.4 million shares for between $15 and $17 per share.

IPO

MORE ON THIS TOPIC

Contemporary art collage. Purple hand holding fan of dollar bills against bright yellow background. stock photo

Collaboration

Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer

February 24, 2026

·

2 min read

·

Tristan Manalac

IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch

IPO tracker

Generate’s IPO Could Reach $425M, Largest Raise Yet

February 24, 2026

·

5 min read

·

Tristan Manalac

Hand collage holding dollar paper money isolated on yellow background. Using cash to buy concept. Halftone effect in pop art style illustration.

Mergers & acquisitions

Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition

February 23, 2026

·

2 min read

·

Tristan Manalac

Collage with colorful casino chips cards dices representing online gambling poker betting e-gaming entertainment.

Collaboration

Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership

February 19, 2026

·

2 min read

·

Tristan Manalac